• 1
    Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;26:916917.
  • 2
    Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001;27:305313.
  • 3
    Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2001;135:306.
  • 4
    Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 2002;97:502503.
    Direct Link:
  • 5
    May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449452.
  • 6
    Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000;132:118121.
  • 7
    Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000;132:121124.
  • 8
    Gouda HE, Khan A, Schwartz J, Cohen RI. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med 2001;111:584585.
  • 9
    Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002;47:16321637.
  • 10
    Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000;95:272276.
    Direct Link:
  • 11
    Koga H, Sakisaka S, Harada M, Takagi T, Hanada S, Taniguchi E, Kawaguchi T, et al. Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 2001;33:10871097.
  • 12
    Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, Brun RP, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94:237241.
  • 13
    Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998;4:10461052.
  • 14
    Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:88068811.
  • 15
    Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB, Hockenbery DM. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol 1997;138:449469.
  • 16
    Kobayashi N, Miyazaki M, Fukaya K, Inoue Y, Sakaguchi M, Uemura T, Noguchi H, et al. Transplantation of highly differentiated immortalized human hepatocytes to treat acute liver failure. Transplantation 2000;69:202207.
  • 17
    Kobayashi N, Miyazaki M, Westerman KA, Noguchi H, Sakaguchi M, Totsugawa T, Watanabe T, et al. Construction of a differentiated human hepatocyte cell line expressing the herpes simplex virus-thymidine kinase gene. ASAIO J 2001;47:476480.
  • 18
    Morrison RF, Farmer SR. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18INK4c and p21Waf1/Cip1, during adipogenesis. J Biol Chem 1999;274:1708817097.
  • 19
    Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM, Arteaga CL. Cyclin-dependent kinase inhibitor p27Kip1 is required for mouse mammary gland morphogenesis and function. J Cell Biol 2001;153:917932.
  • 20
    Deschenes C, Vezina A, Beaulieu JF, Rivard N. Role of p27Kip1 in human intestinal cell differentiation. Gastroenterology 2001;120:423438.
  • 21
    Fukaya K, Asahi S, Nagamori S, Sakaguchi M, Gao C, Miyazaki M, Namba M. Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT. In Vitro Cell Dev Biol Anim 2001;37:266269.
  • 22
    Zhou P, Howley PM. Ubiquitination and degradation of the substrate recognition subunits of SCF ubiquitin-protein ligases. Mol Cell 1998;2:571580.
  • 23
    Koga H, Harada M, Kumemura H, Hanada S, Taniguchi E, Shishido S, Kumashiro R, et al. Skp2 reduction and p27Kip1 accumulation in G1-arrested hepatoma cells through peroxisome proliferator-activated receptor γ activation [Abstract]. Hepatology 2001;34(Part 2):174A.
  • 24
    Kawaguchi T, Sakisaka S, Sata M, Mori M, Tanikawa K. Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis. Hepatology 1999;29:205216.
  • 25
    Maftah A, Petit JM, Ratinaud MH, Julien R. 10-N nonyl-acridine orange: a fluorescent probe which stains mitochondria independently of their energetic state. Biochem Biophys Res Commun 1989;164:185190.
  • 26
    Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, Tufari SR, et al. Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-γ. J Clin Endocrinol Metab 1998;83:28302835.
  • 27
    Davies GF, McFie PJ, Khandelwal RL, Roesler WJ. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-γ expression in hepatocytes. J Pharmacol Exp Ther 2002;300:7277.
  • 28
    Wakabayashi T. Structural changes of mitochondria related to apoptosis: swelling and megamitochondria formation. Acta Biochim Pol 1999;46:223237.
  • 29
    Karbowski M, Kurono C, Wozniak M, Ostrowski M, Teranishi M, Nishizawa Y, Usukura J, et al. Free radical-induced megamitochondria formation and apoptosis. Free Radic Biol Med 1999;26:396409.
  • 30
    Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Macho A, Haeffner A, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996;184:11551160.
  • 31
    Haskins JR, Rowse P, Rahbari R, de la Iglesia FA. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 2001;75:425438.
  • 32
    Kostrubsky VE, Vore M, Kindt E, Burliegh J, Rogers K, Peter G, Altrogge D, et al. The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats. Drug Metab Dispos 2001;29:15611566.
  • 33
    Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxixcity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001;59:627635.
  • 34
    Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:27902799.
  • 35
    Patel T, Steer CJ, Gores GJ. Apoptosis and the liver: a mechanism of disease, growth regulation, and carcinogenesis. Hepatology 1999;30:811815.
  • 36
    Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J Immunol 1983;130:19101917.
  • 37
    Suematsu M, Suzuki H, Ishii H, Kato S, Yanagisawa T, Asako H, Suzuki M, et al. Early midzonal oxidative stress preceding cell death in hypoperfused rat liver. Gastroenterology 1992;103:9941001.
  • 38
    Budd SL, Castilho RF, Nicholls DG. Mitochondrial membrane potential and hydroethidine-monitored superoxide generation in cultured cerebellar granule cells. FEBS Lett 1997;415:2124.
  • 39
    Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000;407:390395.
  • 40
    Izumi T, Enomoto S, Hosiyama K, Sasahara K, Shibukawa A, Nakagawa T, Sugiyama Y. Prediction of the human pharmacokinetics of troglitazone: a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J Pharmacol Exp Ther 1996;277:16301641.
  • 41
    Kawai K, Kawasaki-Tokui Y, Odaka T, Tsuruta F, Kazui M, Iwabuchi H, Nakamura T, et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 1997;47:356368.
  • 42
    Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001;33:10091013.
  • 43
    Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002;22:924929.
  • 44
    Yamamoto Y, Yamazaki H, Ikeda T, Watanabe T, Iwabuchi H, Nakajima M, Yokoi T. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab Dispos 2002;30:155160.
  • 45
    Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 1973;134:707716.
  • 46
    Turrens JF, Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 1980;191:421427.
  • 47
    Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241251.
  • 48
    Buttke TM, Sandstrom PA. Oxidative stress as a mediator of apoptosis. Immunol Today 1994;15:710.
  • 49
    Schewe T, Albracht SP, Ludwig P. On the site of action of the inhibition of the mitochondrial respiratory chain by lipoxygenase. Biochim Biophys Acta 1981;636:210217.
  • 50
    Yang SQ, Zhu H, Li Y, Lin HZ, Gabrielson K, Trush MA, Diel AM. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000;378:259268.
  • 51
    Madesh M, Hajnoczky G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol 2001;155:10031015.
  • 52
    Barja G. Mitochondrial free radical production and aging in mammals and birds. Ann N Y Acad Sci 1998;854:224238.
  • 53
    Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997;18:943948.
  • 54
    You KR, Wen J, Lee SK, Kim DG. Cytochrome c oxidase subunit III: a molecular marker for N-(4-hydroxyphenyl)retinamide-induced oxidative stress in hepatoma cells. J Biol Chem 2002;277:38703877.
  • 55
    Fernandez-Checa JC, Kaplowitz N, Garcia-Ruiz C, Colell A, Miranda M, Mari M, Ardite E, et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol 1997;273:G717.